Drug Profile

Lobeglitazone/sitagliptin - Chong Kun Dang

Alternative Names: CKD-396; Sitagliptin/lobeglitazone - Chong Kun Dang

Latest Information Update: 13 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Chong Kun Dang
Class Amines; Antihyperglycaemics; Fluorinated hydrocarbons; Pyrazines; Pyrimidines; Small molecules; Thiazolidinediones; Triazoles
Mechanism of Action Dipeptidyl peptidase 4 inhibitors; Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor gamma agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

13 Feb 2026 Discontinued - Phase-III for Type 2 diabetes mellitus in South Korea (PO) (Chong Kun Dang pipeline, February 2026)
01 Jun 2021 Phase-III clinical trials in Type 2 diabetes mellitus in South Korea (PO) (Chong Kun Dang Pharmaceutical pipeline, June 2021)
26 Feb 2020 Chemical structure information added

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com